Drugs with substantial evidence for managing CRS include IL-1 inhibitors (e.g., anakinra), IL-6 inhibitors (e.g., tocilizumab), janus kinase inhibitors (JAKi, e.g., baricitinib), and corticosteroids. This evidence concerns the gene IL6 and congenital rubella syndrome.